James M Frates
Chief Financial Officer · 5 filings · Latest: Sep 10, 2026
Amylyx Pharmaceuticals, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
AMLX | James M Frates | Chief Financial Officer | Sep 10, 2026 | Sale | $32.36 | 10,810 | $349.8K | 233,625 | |
AMLX | Frates James M | — | Sep 10, 2026 | Proposed Sale | $32.36 | 10,810 | $349.8K | — | |
AMLX | James M Frates | Chief Financial Officer | Mar 2, 2026 | Sale | $14.52 | 7,909 | $114.9K | 165,638 | |
AMLX | Frates James M | — | Mar 2, 2026 | Proposed Sale | $14.52 | 7,909 | $114.9K | — | |
AMLX | James M Frates | Chief Financial Officer | Feb 2, 2026 | Sale | $14.65 | 3,557 | $52.1K | 173,547 | |
AMLX | Frates James M | — | Feb 2, 2026 | Proposed Sale | $14.65 | 3,557 | $52.1K | — | |
AMLX | Frates James M | — | Jan 6, 2026 | Proposed Sale | $11.11 | 3,326 | $37.0K | — |